Effect of a moderately carbohydrate-restricted diet on liver enzymes, steatosis and fibrosis in normal-weight individuals with non-alcoholic fatty liver disease: study protocol for a parallel randomised controlled clinical trial

(2023) Effect of a moderately carbohydrate-restricted diet on liver enzymes, steatosis and fibrosis in normal-weight individuals with non-alcoholic fatty liver disease: study protocol for a parallel randomised controlled clinical trial. Bmj Open. e063988. ISSN 2044-6055 (Electronic) 2044-6055 (Linking)

Full text not available from this repository.

Abstract

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a hepatic condition that is considerably prevalent across the world. Dietary intakes, in which macronutrient composition is precisely planned, might be able to reduce inflammation, steatosis and fibrosis among patients with NAFLD. A moderately carbohydrate restricted diet with weight loss has been demonstrated to improve liver fat content among overweight or obese patients. However, there is no information about the appropriateness of such a restriction, without weight loss, in normal-weight patients. This randomised clinical trial will be aimed at assessing the effect of moderate carbohydrate restriction on liver enzymes, liver steatosis and fibrosis in normal-weight patients with NAFLD. METHODS AND ANALYSIS: This randomised controlled clinical trial will be conducted to evaluate the impact of a moderately carbohydrate restricted diet on liver enzymes, steatosis and fibrosis in 52 eligible normal-weight individuals with NAFLD. Transient elastography and controlled attenuation parameter with FibroScan will be applied to diagnose NAFLD. After individual matching based on body mass index, age and sex, patients will be randomly assigned to receive a moderately carbohydrate restricted diet or an isocaloric diet without carbohydrate restriction for 12 weeks. The primary and secondary outcomes in this study will be liver function indices, including liver steatosis and fibrosis, metabolic parameters and anthropometric measures. All these variables will be assessed at study baseline and postintervention. ETHICS AND DISSEMINATION: The present clinical trial study was accepted by the ethics committee of TUMS (Tehran University of Medical Sciences) (code: IR.TUMS.MEDICINE.REC.1400.116). TRIAL REGISTRATION NUMBER: IRCT20210119050086N1.

Item Type: Article
Keywords: Humans *Non-alcoholic Fatty Liver Disease/complications Iran Liver/pathology Fibrosis Diet, Carbohydrate-Restricted Carbohydrates Weight Loss Randomized Controlled Trials as Topic Fetal medicine Maternal medicine Nutrition & dietetics
Page Range: e063988
Journal or Publication Title: Bmj Open
Journal Index: Pubmed
Volume: 13
Number: 4
Identification Number: https://doi.org/10.1136/bmjopen-2022-063988
ISSN: 2044-6055 (Electronic) 2044-6055 (Linking)
Depositing User: خانم ناهید ضیائی
URI: http://eprints.mui.ac.ir/id/eprint/27659

Actions (login required)

View Item View Item